| 摘要 |
<p>A combination therapy is provided of IFN-y and therapeutic antibodies that recognize determinants on hyperproliferative B linege cells. The targeted cells are contacted with these agents either locally or systemically, usually systemically. The subject methods provide a means for therapeutic treatment and investigation of hypproliferative disorders.</p> |
